ABIVAX Société Anonyme (NASDAQ:ABVX) Stock Price Down 2.6%

ABIVAX Société Anonyme (NASDAQ:ABVX) traded down 2.6% on Wednesday . The company traded as low as $13.15 and last traded at $13.15. 4,749 shares changed hands during mid-day trading, a decline of 94% from the average session volume of 82,759 shares. The stock had previously closed at $13.50.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Morgan Stanley lifted their price target on ABIVAX Société Anonyme from $15.00 to $16.00 and gave the company an “equal weight” rating in a research note on Thursday, April 11th. Piper Sandler initiated coverage on shares of ABIVAX Société Anonyme in a research report on Monday, April 29th. They issued an “overweight” rating and a $42.00 target price for the company. BTIG Research assumed coverage on shares of ABIVAX Société Anonyme in a research report on Monday, May 20th. They set a “buy” rating and a $43.00 price target on the stock. Finally, Guggenheim started coverage on ABIVAX Société Anonyme in a report on Monday, April 29th. They issued a “buy” rating and a $50.00 price objective for the company. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, ABIVAX Société Anonyme currently has an average rating of “Moderate Buy” and an average target price of $34.20.

ABIVAX Société Anonyme Stock Down 3.2 %

The business’s 50 day simple moving average is $14.02 and its 200 day simple moving average is $13.38. The company has a debt-to-equity ratio of 0.23, a current ratio of 4.08 and a quick ratio of 4.08.

Institutional Trading of ABIVAX Société Anonyme

Hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets acquired a new position in ABIVAX Société Anonyme in the 1st quarter valued at about $81,000. Capstone Investment Advisors LLC acquired a new position in shares of ABIVAX Société Anonyme in the fourth quarter valued at approximately $618,000. Ghisallo Capital Management LLC bought a new position in shares of ABIVAX Société Anonyme during the fourth quarter worth approximately $642,000. Kennedy Capital Management LLC lifted its holdings in ABIVAX Société Anonyme by 35.3% during the 1st quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company’s stock worth $1,718,000 after purchasing an additional 31,331 shares during the last quarter. Finally, Rosalind Advisors Inc. bought a new stake in ABIVAX Société Anonyme in the 1st quarter valued at $5,411,000. 47.91% of the stock is owned by institutional investors and hedge funds.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.